Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194037 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
A Phase 1 study of Chronic Hepatitis C Infection and Genotype 1, sponsored by HanAll BioPharma Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT01194037: Completed Phase 1 study of Chronic Hepatitis C Infection and Genotype 1, sponsored by HanAll BioPharma Co..
NCT01194037 is a Phase 1 study of Chronic Hepatitis C Infection and Genotype 1 that has completed, run by HanAll BioPharma Co.. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01194037, a Phase 1 study of Chronic Hepatitis C Infection and Genotype 1, has completed, sponsored by HanAll BioPharma Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label, randomized, safety, tolerability, dose-finding, PK/PD, and preliminary efficacy study of subcutaneous Hanferon™ in combination with ribavirin(RBV) in treatment-naïve subjects with genotype 1 hepatitis C.
Conditions Studied
Interventions
- DRUG Ribavirin
- DRUG Peginterferon alfa-2a
- DRUG recombinant variant of interferon-alpha 2b
Study Locations (6)
California
- - Los Angeles
- - National City
Florida
- - Miami
Georgia
- - Atlanta
Kentucky
- - Lexington
Louisiana
- - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-06-23 |
| Est. Completion | 2011-11-28 |
| Phase | Phase 1 |
What the finished NCT01194037 record still lists
NCT01194037 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 2 conditions, with Chronic Hepatitis C Infection appearing as the primary indexed condition, and to 3 interventions - of which Ribavirin is the first listed.
NCT01194037 lists 6 locations in 5 states (California, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT01194037 about?
NCT01194037 is a clinical study titled "A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C". This is an open-label, randomized, safety, tolerability, dose-finding, PK/PD, and preliminary efficacy study of subcutaneous Hanferon™ in combination with ribavirin(RBV) in treatment-naïve subjects with genotype 1 hepatitis C.
What is the current status of trial NCT01194037?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2011-06-23. Estimated completion is 2011-11-28.
What conditions does trial NCT01194037 study?
This clinical trial studies the following conditions: Chronic Hepatitis C Infection, Genotype 1.
What interventions are being tested in trial NCT01194037?
The interventions under investigation include: Ribavirin (DRUG), Peginterferon alfa-2a (DRUG), recombinant variant of interferon-alpha 2b (DRUG).
Who is sponsoring clinical trial NCT01194037?
This trial is sponsored by HanAll BioPharma Co., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01194037 being conducted?
This trial has 6 study locations across California, Florida, Georgia, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01194037's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI